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The role of subchondral bone in the progression of osteoarthritis has been controversial for 
nearly 50 years.(1,2)  The observation that subchondral sclerosis was nearly always present in 
end-stage disease led to the conclusion that the increased stiffness caused by a thicker 
subchondral bone plate detracted from the bone’s ability to attenuate the loads imposed on 
the joint cartilage, increasing cartilage stresses and initiating the process of joint 
deterioration. Because cartilage damage does not always progress to full thickness cartilage 
loss and OA, Radin and Rose(3) proposed that the initiation and the progression of cartilage 
deterioration were separate processes. They suggested that it was steep stiffness gradients 
at the joint margins, primarily regions of high tensile and shear stresses that create 
inhomogeneities in the subchondral plate/cartilage complex. They hypothesized that these 
changes caused differential deformation between more compliant and denser regions of the 
subchondral bone, tearing the cartilage attached to it and initiating fibrillation. They further 
proposed that progression of cartilage loss, a separate process, ensued when continued 
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loading occurred on an already dense and stiff subchondral plate. Several animal models 
support this progression of events. In a model of spontaneous age-related OA in 
cynomolgus macaques much like that which occurs in people, Carlson et al.(4,5) clearly 
demonstrated that cartilage damage occurs subsequent to subchondral bone densification.   
 
The paper by Jia et al.(6) examines the mechanisms for subchondral densification, and 
whether increased subchondral plate density is a sine qua non of progressive disease.  To 
do this, they employed several different mouse models, and induced OA with two different 
surgical approaches. They first developed a cartilage-specific knockout of the epidermal 
growth factor receptor (Egfr CKO), which they had previously shown regulates chondrocyte 
number and joint lubrication.(7,8)  They surgically destabilized the medial meniscus (DMM), 
and in some cases hemi-sected the meniscus (DMMH) in Egfr CKO or WT mice, observing 
changes after 2-3 months. To simulate the effects of aging, the authors performed DMM on 
WT mice, observing cartilage changes 10 months after surgery. They also examined the 
spontaneous initiation and progression of OA in Egfr CKO mice over a 12 month period. To 
determine the effect of pre-existing bone densification on the process of cartilage 
degeneration, they also subjected SOST KO mice to DMMH.  This directly tests the Radin 
and Rose hypothesis that increased density and stiffness of the subchondral bone are a 
necessary pre-condition for progression of OA.  If they are, then one might expect an 
accelerated onset of OA, or cartilage degeneration that is more severe than in WT mice. If 
they are not a pre-condition, then the expectation is that cartilage degeneration and the 
development of OA will occur similarly in those mice without pre-existing subchondral 
densification, or not occur at all.  The authors utilized a novel microCT approach that allowed 
them to visualize bone and cartilage changes three-dimensionally, rather than by 2D 
histological serial sectioning. Given the focal nature of cartilage degeneration in OA, 2D 
histological approaches can provide an imperfect view of the relationship between cartilage 
and bone in the regions where cartilage fibrillation occurs.  This new method allowed the 
authors to localize subchondral bone changes to those areas in which cartilage was either 
healthy or degenerating. 
 
What they observed in those models undergoing DMM surgery was a location-specific 
increase in subchondral plate thickness, occurring from the marrow side of the subchondral 
plate, but only at sites of cartilage deterioration and not at sites where the overlying cartilage 
was healthy. This was associated with a localized reduction in sclerostin in subchondral 
bone, increased vessel ingrowth, and more osteoblasts, but only at those sites associated 
with increased thickness and cartilage damage.  These areas were in load-bearing sites of 
the joints; non-loading bearing sites did not show similar cartilage or bone changes. This 
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implicates mechanical loading as complicit in the degenerative process. In situations in 
which there was not cartilage damage, and in non-loadbearing sites, these subchondral 
plate changes did not occur. Interestingly, spontaneous age-related development of cartilage 
damage in the Egfr CKO mice was not localized to the medial weight bearing sites, but was 
also found laterally in association with reduced sclerostin. As has been observed in other 
models in which subchondral plate sclerosis occurs in association with cartilage loss,(9) the 
trabecular bone adjacent to the subchondral plate becomes osteopenic and its 
microarchitecture deteriorates, probably due to the effects of stress shielding.  
 
The authors conclude that subchondral bone sclerosis occurs through a downregulation of 
sclerostin that is fueled by mechanical loading in those regions of the joint in which cartilage 
is breaking down. This is consistent with what we know about the role of sclerostin in 
mechanically-induced bone formation from animal models subjected to in vivo mechanical 
loading.(10)  Two months after DMM surgery, changes in proteoglycan and cartilage 
fibrillation can be seen, at a time when the authors were unable to identify any changes in 
the subchondral bone.   Based on this, they conclude that subchondral sclerosis is 
secondary to the cartilage change, and is driven by the mechanically-mediated down-
regulation of sclerostin.  As further evidence of this, they note that SOST KO mice do not 
develop spontaneous cartilage deterioration, even in mature 14-month-old mice, despite the 
fact that downregulation of SOST results in a significant increase in bone volume and 
density.(11) This is consistent with observations in people who have a gain of function 
mutation of the lipo-protein receptor-related protein 5 (LRP5) gene that leads to high bone 
mass.(12) However, there is no evidence of increased incidence of OA in individuals with this 
mutation compared to the normal population, showing that sclerotic subchondral bone alone 
does not lead to cartilage disease. Animal models also have shown that the existence of 
elevated subchondral density alone  does not lead to cartilage deterioration and OA, unless 
preceded by a period of increased subchondral remodeling and vascularization.  The 
Dunkin-Hartley guinea pig model exhibits a high rate of subchondral bone turnover within the 
first two months of life, and develops severe OA progressively over 12 months.(13)  A second 
guinea pig strain, Strain 13, which, at 2 months of age has a subchondral plate thickness 6-7 
times that of the Dunkin-Hartley model, does not have a high rate of subchondral bone 
turnover, and does not develop evidence of OA.  All these lines of evidence show that 
subchondral plate densification by itself does not initiate joint disease, and the authors make 
this clear when they state: “SBP thickening alone is not sufficient to affect cartilage 
degeneration, and . . . cannot be an initiator of cartilage and joint damage in OA.”  
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When DMMH is performed on SOST KO mice, the resulting cartilage deterioration is no 
worse than it is in WT mice, suggesting that subchondral sclerosis is not driving the 
progression of joint degeneration either, but rather reacting to it. That pre-existing 
subchondral sclerosis does not accelerate the process of joint degeneration or make the OA 
worse may detract from the thesis of Radin and Rose that subchondral sclerosis is required 
for progression of disease once cartilage deterioration has initiated.  But it is not conclusive 
as subchondral sclerosis either exists (SOST KO) or develops (WT) during the process of 
joint destruction.  Evidence that subchondral sclerosis does not contribute to joint 
deterioration would only be conclusive if it could be shown that OA develops even in the 
absence of subchondral sclerosis. Therefore, an experiment like the ones in the Jia study in 
which subchondral bone is prevented from becoming sclerotic (perhaps by performing 
DMMH in a SOST overexpressing mouse, or by preventing increased subchondral plate 
thickness), would provide the negative control needed to conclusively reject the hypothesis 
that subchondral sclerosis is a necessary component of progressive disease.  
Sclerostin is also expressed by chondrocytes,(14) however, and so changes in Wnt signaling 
may also be important to cartilage health either independent of, or concurrent with, changes 
that occur in subchondral bone. A comparison of the expression of Wnt genes in bone 
samples from hip fractures and hip/knee OA showed upregulation of seven genes including 
LRP5 in the OA samples.(15) This led these authors to conclude that Wnt pathway genes not 
only affect the subchondral bone but also regulate cartilage degradation in OA.  This is 
supported by earlier observations that increased β-catenin signaling was associated with an 
OA phenotype in a conditional overexpressing mouse model.(16)  Wnt signaling can be 
induced by pro-inflammatory cytokines(17,18) and cause cartilage matrix degradation by 
stimulating the expression of matrix metalloproteinases (MMPs) and ADAMTS (a disintegrin 
and metalloproteinase with thrombospondin motifs).(19) Shin et al.(20) compared the 
expression of Lrp5, type II collagen and MMPs in human and mouse osteoarthritic cartilage, 
and found a relation between increased Lrp5 expression and cartilage destruction in 
osteoarthritis. On the other hand, Lrp5 deficiency decreased Wnt-mediated cartilage 
destruction. Similar findings were reported in in a study that investigated Wnt signaling and 
Lrp5 expression in human osteoarthritic chondrocytes.(21) Increased Lrp5 expression was 
consistent with cartilage destruction whereas decreased levels reduced the extent of 
cartilage damage.  
Joint instability (DMM) in SOST KO mice leads to higher OA scores, pointing towards the 
significance of sclerostin in maintaining cartilage integrity during mechanical loading.(22) 
Similarly, selective inhibition of the Wnt pathway by Dkk1 decreases the severity of OA. (23)  
However, in both sheep and mouse surgically-induced OA models, SOST was increased in 
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cartilage, but only focally in regions of cartilage damage, while being focally decreased in 
subchondral bone associated with the cartilage damage.(14) The upregulation of SOST in 
these cases seems somewhat contradictory to the idea that increased Wnt signaling 
promotes cartilage degradation. However, this could be a secondary response to the 
increased inflammation associated with the initiation of cartilage degeneration,(17,18) and 
therefore temporal relationships in SOST regulation and Wnt signaling are important to 
study. Preventing expression of SOST and allowing Wnt signaling will increase subchondral 
bone density and may permit the initiation of cartilage degradation, but later stage 
inflammatory processes could stimulate the production of SOST, leading to full thickness 
cartilage loss.  
The observation that increased plate thickness occurs subsequent to the initiation of 
cartilage deterioration does not address whether other changes to subchondral bone that 
occur prior to overt cartilage deterioration contribute to the disease.   Although Jia et al.’s 
work argues against the hypothesis of Radin and Rose that increased subchondral density 
drives progression of disease, this leaves open the question of what initiates the process in 
the first place. There is now accumulating evidence that increased remodeling in the early 
phases of joint disease may be required for progression of disease. This was noted many 
years ago by Li and Aspden(24) who showed that bone in patients with OA was significantly 
less stiff for a given apparent density than normal or osteoporotic bone.  This does not mean 
that the subchondral plate is less stiff at a structural level, and it may not be. However, the 
tissue modulus is lower because of the high turnover and mineralization lag period prior to 
full maturation and mineralization of the tissue.  Day et al.(25) showed that subjects who were 
in the early phases of cartilage loss but not yet arthritic had lower subchondral bone tissue 
modulus, confirming the earlier work of Li and Aspden. The increase in remodeling rate in 
the early phases of OA has been verified using animal models.   
 
When this early remodeling reaction is suppressed using bisphosphonates(26-29) or RANKL 
inhibitors(30,31) that prevent the early increase in remodeling but eventually lead to increased 
subchondral plate thickness, cartilage is protected from progressive deterioration.  The 
protective effect may be both dose- and time- related.  More potent BPs appear to have a 
greater effect,(29) as does treatment earlier in the degenerative process.(32-34)  Although 
suppression of remodeling is not effective at preventing all cartilage damage, early 
suppression is associated with prevention of progressive joint disease.  These studies 
clearly demonstrate that increased bone remodeling is a precursor to OA, and that 
suppression of remodeling in early phase disease can prevent OA even if it leads to 
subchondral densification. 
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The work of Jia et al. is instructive in showing that mechanically-induced downregulation of 
sclerostin provides a mechanism for focally-increased subchondral bone density.  Lower 
sclerostin expression has been shown in bone biopsies from OA patients compared to 
healthy controls,(35) but may not reflect processes involving Wnt signaling in cartilage.(36,37)  In 
the models used by Jia, it would be fascinating to understand the temporal expression of 
SOST in cartilage, and associated changes in Wnt signaling. The data suggest an early 
decrease in sclerostin expression that leads to increased bone density but may also be 
permissive for cartilage degradation, with a subsequent inflammation-related increase in 
cartilage SOST expression. This Wnt signaling link makes the relationship between cartilage 
loss and subchondral bone densification more complex.  Evidence that cartilage loss occurs 
prior to sclerostin downregulation and subsequent densification of subchondral bone has not 
been conclusively shown, and awaits a more thorough temporal analysis of both cartilage 
and bone changes in the models employed here.  The argument over whether osteoarthritis 
initiates in the bone or the cartilage has not been resolved fully, as evidenced by a 
scheduled debate on the topic at the 2018 meeting of the Orthopaedic Research Society.  
One difficulty in resolving this question is that OA is a condition that takes a long time to 
develop.  Therefore, it is difficult to know in humans, if and when early joint changes will 
progress to OA. It is also difficult to determine in those with OA when the process began, or 
what the initiating factor might have been. In this regard, there is a movement towards 
studying post-traumatic OA (PTOA) in which the time of initiation can be identified precisely.  
As PTOA progresses in a way that is consistent with age-related OA (at least macro- and 
microscopically), this is an appropriate way to develop new therapies, even though we don’t 
really know that PTOA and age-related OA are equivalent mechanistically.  
 
It has been suggested that OA is a final common pathway for a multi-etiological set of joint 
diseases and conditions that all lead to the same joint degenerative changes that involve 
both elevated subchondral density and cartilage deterioration and eventual loss. It is 
possible that the final common mechanistic pathway is through Wnt signaling, which both 
accelerates cartilage deterioration and underlies increased subchondral density. This may 
be the long sought link between bone and cartilage change that Radin and his colleagues 
attempted to identify 50 years ago. Based on data in the paper by Jia et al., Radin et al. 
appear to have been correct about the role of mechanical loading.  However, at that time it 
was not possible to identify the molecular link for these events, which only became apparent 
recently with the discovery of the role of the Wnt pathway, and its inhibitors such as SOST 
and DKK. 
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